TICKERNERD
Menu
BMYBMYHealthcare · Drug Manufacturers - General

BMY Stock Forecast: Bristol Myers Squibb Co. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$65
+0.24% on the day

The 27 Wall Street analysts covering Bristol Myers Squibb Co. hold a median 12-month price target of $65 — -0.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 1 Aug 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$133.7B
Ticker Nerd rank
99 / 100
Median analyst target
$65
Analysts covering
27
Total return, dividends reinvested
1W
+4.7%
1M
+12.6%
YTD
+25.4%
1Y
+55.0%
From 52W high
0.0%
From 52W low
+58.8%
$41
$65
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BMY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bristol Myers Squibb Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
99 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
100
Volatility
100
Revisions
97
Issuance
93
Quality
92
Momentum
72
Growth
66
Accruals
65
Size
2

Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (65): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own Bristol Myers Squibb Co. — and when they’d sell — is the membership.

Wall Street

BMY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BMY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$50$60$70$80Oct 25Jan 26Apr 26Jul 26BMYHigh $80Median $65Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says27 analysts
9 Buy17 Hold1 Sell
Low $40Median $65High $80

The green dot is the last close — the median target sits −0.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
31 July 2026Cantor FitzgeraldMaintainsNeutral$54 → $59
31 July 2026GuggenheimMaintainsBuy$72 → $75
31 July 2026JP MorganMaintainsOverweight$67 → $73
31 July 2026RBC CapitalMaintainsSector Perform$60 → $64
31 July 2026Truist SecuritiesReiteratesBuy$65 → $70
31 July 2026Wells FargoMaintainsEqual-Weight$60 → $65
10 July 2026B of A SecuritiesMaintainsBuy$67 → $66
6 July 2026Cantor FitzgeraldReiteratesNeutral$54
9 Apr 2026B of A SecuritiesMaintainsBuy—
8 Apr 2026Cantor FitzgeraldMaintainsNeutral—
8 Apr 2026GuggenheimReiteratesBuy—
17 Mar 2026HSBCMaintainsHold—
25 Feb 2026RBC CapitalInitiatesSector Perform—
23 Feb 2026Piper SandlerMaintainsOverweight—
20 Feb 2026BarclaysInitiatesOverweight—
6 Feb 2026CitigroupMaintainsNeutral—
6 Feb 2026GuggenheimMaintainsBuy—
6 Feb 2026Wells FargoMaintainsEqual-Weight—
28 Jan 2026Piper SandlerMaintainsOverweight—
27 Jan 2026CitigroupMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

BMY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.3%
Analysts raising
6
Analysts cutting
1
Fundamentals

Bristol Myers Squibb Co. (BMY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
14.4×

Cheaper than 49% of US stocks

Price / sales
2.7×

Cheaper than 45% of US stocks

Price / book
6.0×

Cheaper than 17% of US stocks

EV / EBITDA
8.8×

Cheaper than 43% of US stocks

Growth & margins
Revenue growth (YoY)
5.7%

Higher than 43% of US stocks

Earnings growth (YoY)
153.2%

Higher than 90% of US stocks

Gross margin
71.3%

Higher than 84% of US stocks

Operating margin
34.4%

Higher than 90% of US stocks

Net margin
18.9%

Higher than 81% of US stocks

Returns & dividend
Return on equity
46.6%

Higher than 92% of US stocks

Return on assets
10.7%

Higher than 93% of US stocks

Dividend yield
3.8%

Higher than 75% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BMY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
BMYBristol Myers Squibb Co.$133.7B
99
PFEPfizer Inc.$142.2B
69
GILDGilead Sciences, Inc.$161.6B
89
AMGNAmgen, Inc.$207.6B
86
MRKMerck & Co., Inc.$323.2B
69
ABBVAbbVie, Inc.$443.4B
91
BIIBBiogen, Inc.$29.8B
68
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BMY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest BMY news & analysis

More Biotech M&A Is on the Way, Whether an AstraZeneca-Bristol Myers Deal Happens or Not

Barrons · 4 Aug 2026positive

The article reports that more M&A activity is expected in the biopharma sector, whether or not an AstraZeneca-Bristol Myers merger takes place. It notes that investors stand to benefit from this wave of deal-making even if a megamerger fails to materialize.

Why it matters — A BMY watcher would care because potential sector-wide M&A, including a possible AstraZeneca-Bristol Myers deal, could affect the company's outlook and investor sentiment.

Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”

24/7 Wall Street · 3 Aug 2026positive

A top healthcare analyst proposed a potential $400 billion merger between AstraZeneca and Bristol Myers Squibb, arguing that combining the two companies could significantly cut costs.

Why it matters — BMY watchers would care because the deal speculation highlights a potential major strategic move that could reshape the company's cost structure and competitive position in the pharmaceutical industry.

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

Benzinga · 3 Aug 2026neutral

According to a weekend media report, AstraZeneca and Bristol Myers Squibb are in potential discussions to form a pharmaceutical giant valued at nearly $400 billion, with patent expiration and deal economics reportedly in focus. No confirmation or further terms were provided in the excerpt.

Why it matters — For Bristol Myers Squibb shareholders, a merger of this scale could significantly reshape the company's size, portfolio, and strategy around upcoming patent expirations.

Bristol-Myers stock: why AstraZeneca merger is unlikely to happen

Invezz · 3 Aug 2026negative

Bristol-Myers Squibb shares fell after reports emerged that AstraZeneca held preliminary merger discussions with the company, though analysts view a transatlantic megamerger as unlikely.

Why it matters — BMY watchers would care because merger speculation can create short-term stock volatility even if the deal is considered improbable.

Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

Zacks Investment Research · 3 Aug 2026positive

Zacks Investment Research highlighted Bristol Myers Squibb as a top value stock for the long term, using its Zacks Style Scores to identify the company as a strong value-oriented pick.

Why it matters — A BMY watcher would care because the item positions the company favorably among value stocks, reinforcing its appeal to long-term investors.

FAQ

Frequently asked questions about BMY stock

What is the BMY stock price forecast for 2026-2027?

The 27 Wall Street analysts covering Bristol Myers Squibb Co. have a median 12-month price target of $65, with estimates ranging from $40 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BMY stock a buy right now?

Of the 27 analysts covering Bristol Myers Squibb Co., 9 rate it a Buy, 17 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bristol Myers Squibb Co. 99 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BMY?

As at 1 Aug 2026, Bristol Myers Squibb Co. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).

Will BMY stock go up?

No one can know that. What the data says: the median 12-month target from 27 analysts implies -0.7% from the last close, and Ticker Nerd's factor model ranks Bristol Myers Squibb Co. 99 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BMY stock forecast for 2030?

No analyst covering Bristol Myers Squibb Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $80 over the next 12 months.

How has BMY stock performed over the past year?

Bristol Myers Squibb Co. returned +55.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bristol Myers Squibb Co. do?

Bristol-Myers Squibb Company is a global biopharmaceutical company headquartered in Princeton, New Jersey, and founded in 1933. It discovers, develops, licenses, manufactures, markets, distributes, and sells innovative medicines addressing serious diseases worldwide.

What is the latest news on BMY?

The most recent item we track (Barrons, 4 Aug 2026): "More Biotech M&A Is on the Way, Whether an AstraZeneca-Bristol Myers Deal Happens or Not". The article reports that more M&A activity is expected in the biopharma sector, whether or not an AstraZeneca-Bristol Myers merger takes place. It notes that investors stand to benefit from this wave of deal-making even if a megamerger fails to materialize.

Company

About Bristol Myers Squibb Co.

Bristol-Myers Squibb Company is a global biopharmaceutical company headquartered in Princeton, New Jersey, and founded in 1933. It discovers, develops, licenses, manufactures, markets, distributes, and sells innovative medicines addressing serious diseases worldwide. The company offers a diverse portfolio including small molecule drugs, biologics produced from biological processes, and advanced chimeric antigen receptor (CAR-T) cell therapies. Key therapeutic areas encompass oncology with treatments like nivolumab (Opdivo) and ipilimumab (Yervoy), hematology featuring lenalidomide (Revlimid) and luspatercept (Reblozyl), immunology such as abatacept (Orencia), cardiovascular including apixaban (Eliquis), neuroscience, and other immunology and fibrosis-related conditions. Bristol-Myers Squibb Company plays a vital role in the healthcare sector by providing therapies for cancer, immune disorders, cardiovascular diseases, and beyond, serving patients through collaborations and a focus on unmet medical needs in these critical markets.

CEO Dr. Christopher S. Boerner Ph.D. · 32,500 employees · United States · https://www.bms.com